Compounded GLP-1 and NAD+ Injections Recalled Due to Sterility Issues

Apothecary Pharma LLC has issued a nationwide recall for 22 vials of compounded tirzepatide (GLP-1) and one NAD+ vial. This Class II recall, prompted by a May 2025 FDA inspection citing insanitary sterile drug production conditions, is due to a lack of sterility assurance. While serious health outcomes are unlikely, temporary or reversible adverse effects are possible, impacting patients using these specific compounded medications.